Decay-accelerating factor induction by tumour necrosis factor-α, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition

Immunology

Volumn 110, Issue 2, 2003, Pages 258-268

  Ahmad, Saifur R ^a   Lidington, Elaine A ^a   Ohta, Rieko ^b   Okada, Noriko ^b   Robson, Michael G ^a   Davies, Kevin A ^a,c,e   Leitges, Michael ^c,e   Harris, Claire L ^d   Haskard, Dorian O ^a   Mason, Justin C ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT RECEPTOR RELATED PROTEIN Y; DECAY ACCELERATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CELL STIMULATION; CELLULAR DISTRIBUTION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVITY; FLOW CYTOMETRY; GLOMERULONEPHRITIS; GLOMERULUS CAPILLARY; IMMUNOASSAY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VASCULAR ENDOTHELIUM;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIGENS, CD55; CELLS, CULTURED; COMPLEMENT ACTIVATION; COMPLEMENT C3; ENDOTHELIUM, VASCULAR; GLOMERULONEPHRITIS; IMMUNE COMPLEX DISEASES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEIN KINASE C; RECEPTORS, COMPLEMENT; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 0141888345     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2003.01733.x     Document Type: Article

References (47)

1. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140-4.
2. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology and function. Annu Rev Immunol 1989; 7:35-58.
3. Okada N, Harada R, Fujita T, Okada H. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol 1989; 1:205-8.
4. Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): newest member of the regulators of the complement activation gene cluster. Annu Rev Immunol 1991; 9: 431-55.
5. Molina H, Wong W, Kinoshita T, Brenner C, Foley S, Holers VM. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med 1992; 175:121-9.
6. Kim YU, Kinoshita T, Molina H, Hourcade D, Seya T, Wagner LM, Holers VM. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med 1995; 181:151-9.
7. Medof ME, Kinoshita T, Silber R, Nussenzweig V. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci USA 1985; 82: 2980-4.
8. Spicer AP, Seldin MF, Gendler SJ. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. J Immunol 1995; 155:3079-91.
9. Fukuoka Y, Yasui A, Okada N, Okada H. Molecular cloning of murine decay-accelerating factor by immunoscreening. Int Immunol 1996; 8:379-85.
10. Song W-C, Deng C, Raszmann K, Moore R, Newbold R, McLachlan JA, Negishi M. Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J Immunol 1996; 157:4166-72.
11. Harris CL, Rushmere NK, Morgan BP. Molecular and functional analysis of mouse decay-accelerating factor (CD55). Biochem J 1999; 341:821-9.
12. Miwa T, Sun X, Ohta R, Okada N, Harris CL, Morgan BP, Song W-C. Characterization of glycosylphosphatidylinositol-anchored decay-accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity. Immunology 2001; 104:207-14.
13. Lin F, Fukuoka Y, Spicer A et al. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 2001; 104:215-25.
14. Sun X, Funk CD, Deng C, Sahu A, Lambris JD, Song W-C. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sei USA 1999; 96:628-33.
15. Miwa T, Zhou L, Hilliard B, Molina H, Song W-C. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack. Blood 2002; 99: 3707-16.
16. Sogabe H, Nangaku M, Ishibashi Y et al. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol 2001; 167: 2791-7.
17. Lin F, Emancipator SN, Salant DJ, Medof ME. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lab Invest 2002; 82: 563-9.
18. Mason JC, Yarwood H, Sugars K, Morgan BP, Davies KA, Haskard DO. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood 1999; 94:1673-82.
19. Lidington EA, Haskard DO, Mason JC. Induction of decay-accelerating factor by thrombin through a protease-activated receptor1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood 2000; 96: 2784-92.
20. Mason JC, Lidington EA, Yarwood H, Lublin DM, Haskard DO. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor - a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthritis Rheum 2001; 44:138-50.
21. Mason JC, Lidington EA, Ahmad SR, Haskard DO. bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor upregulation. Am J Physiol Cell Physiol 2002; 282:C578-87.
22. Ohta R, Imai M, Fukuoka Y, Miwa T, Okada N, Okada H. Characterization of mouse DAF on transfectant cells using monoclonal antibodies which recognize different epitopes. Microbiol Immunol 1999; 43:1045-56.
23. Dekker LV, Leitges M, Altschuler G, Mistry N, McDermott A, Roes J, Segal AW. Protein kinase C-β contributes to NADPH oxidase activation in neutrophils. Biochem J 2000; 347:285-9.
24. Leitges M, Schmedt C, Guinamard R, Davoust J, Schaal S, Stabel S, Tarakhovsky A. Immunodeficiency in protein kinase Cβ-deficient mice. Science 1996; 273:788-91].
25. Castrillo A, Pennington DJ, Otto F, Parker PJ, Owen MJ, Bosca L. Protein kinase Cε is required for macrophage activation and defense against bacterial infection. J Exp Med 2001; 194:1231-42.
26. Jat PS, Noble MD, Ataliotis P, Tanaka Y, Yannoutsos N, Larsen L, Kioussis D. Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc Natl Acad Sci USA 1991; 88:5096-100.
27. Lidington EA, Rao RM, Marelli-Berg FM, Jat PS, Haskard DO, Mason JC. Conditional immortalization of growth factor-responsive cardiac endothelial cells from H-2Kb-tsA58 mice. Am J Physiol Cell Physiol 2002; 282:C67-74.
28. Robson MG, Cook HT, Botto M et al. Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J Immunol 2001; 166:6820-8.
29. Toullec D, Pianetti P, Coste H et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 1991; 266:15771-81.
30. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marme D, Schachtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö6976. J Biol Chem 1993; 268:9194-7.
31. Eichholtz T, de Bont D, de Widt J, Liskamp R, Ploegh H. A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor. J Biol Chem 1993; 268:1982-6.
32. Assmann KJ, Tangelder MM, Lange WP, Schrijver G, Koene RA. Anti-GBM nephritis in the mouse: severe proteinuria in the heterologous phase. Virchows Arch a Pathol Anat Histopathol 1985; 406:285-99.
33. Karkar AM, Tam FW, Steinkasserer A Kurrle R, Langner K, Scallon BJ, Meager A, Rees, AJ. Modulation of antibody-mediated glomerular injury in vivo by IL-1RA, soluble IL-1 receptor, and soluble TNF receptor. Kidney Int 1995; 48:1738-46.
34. Funabashi K, Okada N, Matsuo S, Yamamoto T, Morgan BP, Okada H. Tissue distribution of complement regulatory membrane proteins in rats. Immunology 1994; 81:444-51.
35. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H. A critical role for murine complement regulator Crry in fetomaternal tolerance. Science 2000; 287:498-501.
36. Pangburn MK, Muller-Eberhard HJ. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med 1980; 152: 1102-14.
37. Manderson AP, Pickering MC, Botto M, Walport MJ, Parish CR. Continual low-level activation of the classical complement pathway. J Exp Med 2001; 194:747-56.
38. Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1989; 264:1-14.
39. Rahman A, Anwar KN, Malik AB. Protein kinase C-ζ mediates TNF-alpha-induced ICAM-1 gene transcription in endothelial cells. Am J Physiol Cell Physiol 2000; 279:C906-14.
40. Surapisitchat J, Hoefen RJ, Pi X, Yoshizumi M, Yan C, Berk BC. Fluid shear stress inhibits TNF-α activation of JNK but not ERK1/2 or p38 in human umbilical vein endothelial cells: inhibitory crosstalk among MAPK family members. Proc Natl Acad Sci USA 2001; 98:6476-81.
41. Yamamori T, Inanami O, Nagahata H, Cui Y, Kuwabara M. Roles of p38 MAPK, PKC and P13-K in the signaling pathways of NADPH oxidase activation and phagocytosis in bovine polymorphonuclear leukocytes. FEBS Lett 2000; 467:253-8.
42. von Lindern M, Parren-Van Amelsvoort M, van Dijk T et al. Protein kinase Cα controls erythropoietin receptor signaling. J Biol Chem 2000; 275:34719-27.
43. Awasthi S, Vivekananda J, Awasthi V, Smith D, King RJ. CTP phosphocholine cytidylyltransferase inhibition by ceramide via PKC-α, p38 MAPK, cPLA2, and 5-lipoxygenase. Am J Physiol Lung Cell Mol Physiol 2001; 281:L108-18.
44. Podar K, Tai Y-T, Lin BK et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKCα activation. J Biol Chem 2002; 277:7875-81.
45. Collard CD, Bukusoglu C, Agah A, Colgan SP, Reenstra WR, Morgan BP, Stahl GL. Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells. Am J Physiol 1999; 276:C450-8.
46. Hamann J, Vogel B, van Schijndel GMW, van Lier RAW. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55 DAF). J Exp Med 1996; 184:1185-9.
47. Hamann J, van Zeventer C, Bijl A, Molenaar C, Tesselaar K, van Lier RA. Molecular cloning and characterization of mouse CD97. Int Immunol 2000; 12:439-48.